Arming an Oncolytic Herpes Simplex Virus Type 1 with a Single-chain Fragment Variable Antibody against PD-1 for Experimental Glioblastoma Therapy

PURPOSE: Glioblastoma (GBM) is resistant to standard of care. Immune checkpoints inhibitors (such as anti-PD-1 mAbs) efficiently restore antitumor T-cell activity. We engineered a new oncolytic herpes simplex virus (oHSV) expressing a single-chain antibody against PD-1 (scFvPD-1) to evaluate its eff...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Passaro, Carmela, Alayo, Quazim, De Laura, Isabella, McNulty, John, Grauwet, Korneel, Ito, Hirotaka, Bhaskaran, Vivek, Mineo, Marco, Lawler, Sean E., Shah, Khalid, Speranza, Maria C., Goins, William, McLaughlin, Eric, Fernandez, Soledad, Reardon, David A., Freeman, Gordon J., Chiocca, E. Antonio, Nakashima, Hiroshi
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6800097/
https://ncbi.nlm.nih.gov/pubmed/30279232
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-2311
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados